A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

This study tests JAB-21822, a targeted drug for non-small cell lung cancer (NSCLC) that has a specific combination of genetic mutations: KRAS G12C mutation, STK11 co-mutation, and wild-type (normal) KEAP1. **You may be eligible if...** - You have locally advanced or metastatic NSCLC confirmed by molecular testing - Your tumor has both the KRAS G12C mutation and an STK11 co-mutation, with normal KEAP1 - You are treatment-naive or have received at least one prior standard therapy for advanced NSCLC - Your performance status is good (ECOG 0–1) **You may NOT be eligible if...** - You have active, untreated brain metastases or cancer spread to the lining around the brain - You have had radiation therapy within 3 weeks before starting treatment - You have an active infection requiring treatment - You have other serious uncontrolled medical conditions Talk to your doctor to see if this trial is right for you.